| Year |
Citation |
Score |
| 2021 |
Singleton DC, Mowday AM, Guise CP, Syddall SP, Bai SY, Li D, Ashoorzadeh A, Smaill JB, Wilson WR, Patterson AV. Bioreductive prodrug PR-104 improves the tumour distribution and titre of the nitroreductase-armed oncolytic adenovirus ONYX-411 leading to therapeutic benefit. Cancer Gene Therapy. PMID 34837065 DOI: 10.1038/s41417-021-00409-2 |
0.584 |
|
| 2019 |
Liew LP, Singleton DC, Wong WW, Cheng GJ, Jamieson SMF, Hay M. Hypoxia Activated Prodrugs of PERK Inhibitors. Chemistry, An Asian Journal. PMID 30615821 DOI: 10.1002/asia.201801826 |
0.301 |
|
| 2016 |
McIntyre A, Hulikova A, Ledaki I, Snell C, Singleton D, Steers G, Seden P, Jones D, Bridges E, Wigfield S, Li JL, Russell A, Swietach P, Harris AL. Disrupting hypoxia-induced bicarbonate transport acidifies tumor cells and suppresses tumor growth. Cancer Research. PMID 27197160 DOI: 10.1158/0008-5472.Can-15-1862 |
0.588 |
|
| 2014 |
Singleton DC, Rouhi P, Zois CE, Haider S, Li JL, Kessler BM, Cao Y, Harris AL. Hypoxic regulation of RIOK3 is a major mechanism for cancer cell invasion and metastasis. Oncogene. PMID 25486436 DOI: 10.1038/onc.2014.396 |
0.707 |
|
| 2014 |
Pettersen EO, Ebbesen P, Gieling RG, Williams KJ, Dubois L, Lambin P, Ward C, Meehan J, Kunkler IH, Langdon SP, Ree AH, Flatmark K, Lyng H, Calzada MJ, Peso LD, ... ... Singleton DC, et al. Targeting tumour hypoxia to prevent cancer metastasis. From biology, biosensing and technology to drug development: the METOXIA consortium. Journal of Enzyme Inhibition and Medicinal Chemistry. 1-33. PMID 25347767 DOI: 10.3109/14756366.2014.966704 |
0.596 |
|
| 2013 |
Singleton DC, Harris AL. Microenvironmental induced essentiality of autophagy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 2791-3. PMID 23613319 DOI: 10.1158/1078-0432.CCR-13-0634 |
0.539 |
|
| 2013 |
Kumar K, Wigfield S, Gee HE, Devlin CM, Singleton D, Li JL, Buffa F, Huffman M, Sinn AL, Silver J, Turley H, Leek R, Harris AL, Ivan M. Dichloroacetate reverses the hypoxic adaptation to bevacizumab and enhances its antitumor effects in mouse xenografts. Journal of Molecular Medicine (Berlin, Germany). 91: 749-58. PMID 23361368 DOI: 10.1007/s00109-013-0996-2 |
0.623 |
|
| 2013 |
Pike LR, Singleton DC, Buffa F, Abramczyk O, Phadwal K, Li JL, Simon AK, Murray JT, Harris AL. Transcriptional up-regulation of ULK1 by ATF4 contributes to cancer cell survival. The Biochemical Journal. 449: 389-400. PMID 23078367 DOI: 10.1042/Bj20120972 |
0.739 |
|
| 2012 |
Singleton DC, Harris AL. Targeting the ATF4 pathway in cancer therapy. Expert Opinion On Therapeutic Targets. 16: 1189-202. PMID 23009153 DOI: 10.1517/14728222.2012.728207 |
0.496 |
|
| 2009 |
Dachs GU, Hunt MA, Syddall S, Singleton DC, Patterson AV. Bystander or no bystander for gene directed enzyme prodrug therapy. Molecules (Basel, Switzerland). 14: 4517-45. PMID 19924084 DOI: 10.3390/molecules14114517 |
0.581 |
|
| 2009 |
Rzymski T, Milani M, Singleton DC, Harris AL. Role of ATF4 in regulation of autophagy and resistance to drugs and hypoxia. Cell Cycle (Georgetown, Tex.). 8: 3838-47. PMID 19887912 DOI: 10.4161/cc.8.23.10086 |
0.736 |
|
| 2007 |
Singleton DC, Li D, Bai SY, Syddall SP, Smaill JB, Shen Y, Denny WA, Wilson WR, Patterson AV. The nitroreductase prodrug SN 28343 enhances the potency of systemically administered armed oncolytic adenovirus ONYX-411(NTR). Cancer Gene Therapy. 14: 953-67. PMID 17975564 DOI: 10.1038/sj.cgt.7701088 |
0.345 |
|
| Show low-probability matches. |